GNA14 Antibody

What is GNA14 and what cellular functions does it serve?

GNA14 is a guanine nucleotide-binding protein subunit alpha-14 with a molecular weight of approximately 42 kDa. It belongs to the Gαq subfamily of G proteins that function as modulators or transducers in various transmembrane signaling systems . G proteins like GNA14 are involved in transmitting signals from cell surface receptors to intracellular effectors.

Recent research reveals that GNA14 plays critical roles in multiple biological functions including cardiovascular development, angiogenesis, and regulation of cancer progression . Unlike some other members of the Gαq subfamily that promote tumor development, GNA14 has been identified as a potential tumor suppressor in hepatocellular carcinoma (HCC) .

How can I detect GNA14 protein expression in my experimental samples?

GNA14 protein expression can be detected using several methods:

For optimal results in Western blot analysis, mouse lung tissue lysate has been confirmed as a positive control . For IHC applications, human prostate cancer tissue and kidney tissue have shown positive staining . When performing IF, HeLa and HepG2 cells have demonstrated positive results .

What are the recommended protocols for GNA14 antibody applications?

For Western blot analysis of GNA14:

• Prepare protein lysates from your samples of interest

• Separate proteins by SDS-PAGE (expect a band at approximately 42 kDa)

• Transfer to a membrane and block with appropriate blocking buffer

• Incubate with primary GNA14 antibody (1:200-1:1000 dilution)

• Wash and incubate with appropriate secondary antibody

• Develop and visualize

For IHC applications, antigen retrieval is crucial:

• Deparaffinize and rehydrate tissue sections

• Perform heat-induced epitope retrieval using TE buffer (pH 9.0) or citrate buffer (pH 6.0)

• Block endogenous peroxidase and non-specific binding

• Incubate with GNA14 antibody (1:50-1:500)

• Apply detection system and counterstain

How does GNA14 function in cancer biology, particularly in hepatocellular carcinoma?

GNA14 appears to have a tumor-suppressive role in hepatocellular carcinoma, which differs from some other Gαq subfamily members:

This stands in contrast to previous understanding of Gαq subfamily proteins, which typically stimulate downstream pathways through PLC or Ras activation.

What methodologies can I use to study GNA14 protein interactions?

Based on published research, several methodologies have been successfully used to identify and validate GNA14 protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Treat cells with TPA (200 nM) and MG132 (20 μM) for 30 min

  • Collect and lyse cells

  • Immobilize GNA14 or interacting protein antibody (e.g., RACK1) on AminoLink Plus coupling resin

  • Incubate with cell lysates

  • Wash and elute bound proteins

  • Analyze by Western blot

• Mass Spectrometry for novel interactor identification:

  • Perform immunoprecipitation with GNA14 antibody

  • Separate proteins by SDS-PAGE

  • Stain with Coomassie Blue

  • Excise bands of interest

  • Perform in-gel trypsin digestion

  • Analyze peptides by mass spectrometry (e.g., LTQ Orbitrap Velos Pro)

• GST Pull-down assay:

  • Express GNA14 as a GST fusion protein

  • Incubate with cell lysates or purified proteins

  • Capture complexes using glutathione resin

  • Analyze binding partners by Western blot

These approaches successfully identified RACK1 as a direct binding partner of GNA14 in hepatocellular carcinoma research.

What are the signaling pathways regulated by GNA14 and how can I investigate them?

GNA14 regulates several key signaling pathways, particularly in cancer contexts:

• PI3K/AKT pathway: GNA14 suppresses AKT phosphorylation through its interaction with RACK1 .

• MAPK/JNK pathway: GNA14 reduces JNK activation, affecting downstream cellular processes .

To investigate these pathways:

• Pathway Reporter Arrays: The Cignal Finder 10-Pathway Reporter Array has been used successfully to identify pathways mediated by GNA14. This assay employs reporter constructs for multiple signaling pathways simultaneously .

• Western blotting: Examine phosphorylation status of key signaling proteins (p-AKT, p-JNK) after GNA14 manipulation (overexpression or knockdown).

• Combined pharmacological approach: GNA14 has been shown to synergize with U73122 (PLC inhibitor) to enhance the inhibition of signaling pathways, suggesting combination approaches for pathway studies .

• RNA-Seq analysis: Transcriptome profiling after GNA14 manipulation can identify downstream effectors and transcriptional changes resulting from altered signaling pathway activity .

How can I ensure specificity when using GNA14 antibodies?

To ensure specificity of GNA14 antibodies:

• Use proper controls:

  • Positive controls: Mouse lung tissue for WB; human prostate cancer or kidney tissue for IHC; HeLa or HepG2 cells for IF

  • Negative controls: Tissues or cells known to have low/no GNA14 expression

  • IgG controls: Use appropriate isotype control antibodies

• Validate with multiple techniques:

  • Confirm protein expression using different applications (WB, IHC, IF)

  • Use siRNA/shRNA knockdown samples as negative controls

  • Compare results from antibodies targeting different epitopes of GNA14

• Optimize protocols:

  • Titrate antibody concentration (1:200-1:1000 for WB, 1:50-1:500 for IHC)

  • Test different antigen retrieval methods (TE buffer pH 9.0 or citrate buffer pH 6.0 for IHC)

  • Adjust blocking conditions to reduce background

What are the best quantification methods for GNA14 expression in tumor samples?

For accurate quantification of GNA14 expression in tumor samples:

• IHC scoring system:

  • Use a standardized scoring system (e.g., IHC score < 4 for low expression, ≥ 4 for high expression as used in HCC studies)

  • Evaluate both intensity and percentage of positive cells

  • Have multiple pathologists score independently to reduce bias

• RT-qPCR for mRNA quantification:

  • Use validated primers specific for GNA14

  • Normalize to appropriate housekeeping genes

  • Compare tumor tissue with adjacent non-tumor tissue

• Western blot quantification:

  • Use densitometry analysis of band intensity

  • Normalize to loading controls (β-actin, GAPDH)

  • Include standard curves for absolute quantification

• RNA-Seq analysis:

  • For large-scale studies, RNA-Seq data can provide comprehensive expression profiles

  • Analyze existing datasets (e.g., TCGA-LIHC) to correlate GNA14 expression with clinical parameters

How can I optimize co-immunoprecipitation experiments with GNA14 antibodies?

For successful co-immunoprecipitation of GNA14 and its binding partners:

• Cell treatment optimization:

  • Treat cells with TPA (200 nM) and proteasome inhibitor MG132 (20 μM) for 30 minutes before lysis to stabilize protein interactions

  • Consider crosslinking to capture transient interactions

• Lysis conditions:

  • Use mild lysis buffers to preserve protein-protein interactions

  • Include protease and phosphatase inhibitors

  • Avoid harsh detergents that might disrupt protein complexes

• Antibody coupling:

  • Pre-couple antibodies to beads (e.g., AminoLink Plus coupling resin)

  • Determine optimal antibody amount (typically 2-5 μg per reaction)

  • Include IgG control to identify non-specific binding

• Washing conditions:

  • Optimize salt concentration and detergent levels in wash buffers

  • Perform sufficient wash steps to reduce background

  • Consider including increasing stringency washes

• Elution and detection:

  • Use appropriate elution conditions that don't interfere with downstream applications

  • Analyze by Western blot using specific antibodies against GNA14 and suspected binding partners

  • Consider mass spectrometry for unbiased interaction discovery

How can I correlate GNA14 expression with clinical outcomes in cancer research?

To correlate GNA14 expression with clinical outcomes:

In HCC research, low GNA14 expression was identified as an independent risk factor for both OS (95% CI, 1.168–2.699, P = 0.009) and DFS (95% CI, 1.267–3.628, P = 0.007) after liver resection in multivariate analysis .

How do I interpret contradictory findings regarding GNA14 function in different cancer types?

When faced with contradictory findings about GNA14 function across different cancer types:

• Context-specific evaluation:

  • Different cellular contexts may result in different GNA14 functions

  • GNA14 acts as a tumor suppressor in HCC , but may have different roles in other cancers

  • For example, one study showed GNA14 silencing suppressed proliferation in endometrial carcinoma cells, contradicting its role in HCC

• Mechanistic analysis:

  • Identify the downstream pathways affected by GNA14 in each cancer type

  • In HCC, GNA14 inhibits PI3K/AKT and MAPK/JNK pathways through RACK1 interaction

  • Evaluate binding partners like RACK1 across different cancer types

• Experimental validation:

  • Perform both gain- and loss-of-function experiments

  • Use multiple cell lines representing different cancer types

  • Corroborate in vitro findings with patient data

• Integrated analysis:

  • Combine transcriptomic, proteomic, and functional data

  • Consider the influence of tumor microenvironment

  • Evaluate mutations or post-translational modifications that might alter GNA14 function

For example, in HCC research, the role of GNA14 was found to be "potentially different from the understanding of Gαq subfamily we had known before," highlighting the importance of context-specific investigation .